SARS-CoV-2 (Omicron) Neutralizing Antibody Standard

USA

-20°C

The product is specific for SARS-CoV-2 RBD domain. The product can recognize and neutralize Wild-Type SARS-CoV-2 and five Variants of Concern (VOC) including Alpha, Beta, Gamma, Delta, and Omicron.

Recombinant SARS-CoV-2 RBD Protein

Protein A affinity column

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) is a positive-sense single-stranded RNA virus. It caused coronavirus disease 2019 (COVID-19). The B.1.1.529 variant was first reported to WHO from South Africa on 24 November 2021. WHO has designated B.1.1.529 as a VOC, named Omicron. SARS-CoV-2 contains glycosylated spike (S) protein, which is composed of S1 subunit and S2 subunit. The S1 contains a receptor-binding domain (RBD) that can bind to ACE2 receptor on target cells. Neutralizing antibodies against SARS-CoV-2 can block the interaction between SARS-CoV-2 RBD and ACE2. The blocking ability of SARS-CoV-2 neutralizing antibodies is affected by the quantity. This standard product is intended for the calibration of SARS-CoV-2 Omicron neutralizing antibodies. It can be used in the assessment and development of assays for the detection and quantitation of SARS-CoV-2 Omicron neutralizing antibodies. The neutralizing antibody standard binds to multiple neutralizing epitopes in the receptor-binding domain.